The Application of Evidence-Based Principles of Care in Older Persons (Issue 3): Management of Diabetes Mellitus

Journal of the American Medical Directors Association

Volumn 7, Issue 4, 2006, Pages 234-240

  Zarowitz, Barbara J ^a,b   Tangalos, Eric G ^c   Hollenack, Kelly ^a   O'Shea, Terry ^a  

^a Omnicare Inc   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; IRBESARTAN; ISOPHANE INSULIN; LOSARTAN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SULFONYLUREA; VERAPAMIL;

AGED; ALGORITHM; ARTICLE; BLOOD PRESSURE REGULATION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ELDERLY CARE; EVIDENCE BASED PRACTICE; FEAR; FRAIL ELDERLY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NURSING HOME; PATIENT ATTITUDE; PATIENT CARE; UNCERTAINTY;

EID: 33646384383     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.01.002     Document Type: Article

References (38)

1. Prevalence of diabetes in 500,000 residents of long-term care facilities in the United States. Proprietary administrative data (2004), Omnicare, Inc
2. Haines S.T. The diabetes epidemic. Can we stop the spread?. Pharmacother 23 (2003) 1227-1231
3. National Diabetes Information Clearing House. National Diabetes Statistics. NIH Publication No. 06-3892 November 2005.
4. Diabetes in America. National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995. NIH Publication No. 95-1468.
5. Gregg E.W., Mangione C.M., Cauley J.A., et al. Diabetes and incidence of functional disability in older women. Diabetes Care 25 (2002) 61-67
6. Travis S.S., Buchanan R.J., Wang S., and Kim M.S. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc 4 (2004) 320-327
7. Gilmer T.P., O'Connor P.J., Rush W.J., et al. Predictors of health care costs in adults with diabetes. Diabetes Care 28 (2005) 59-64
8. Franse L.V., Di Bari M., Shorr R.I., et al. Type 2 diabetes in older well-functioning people: Who is undiagnosed? Data from the Health, Aging, and Body Composition Study. Diabetes Care 24 (2001) 2065-2070
9. National Committee for Quality Assurance. State of Heath Care Quality (2004), National Committee for Quality Assurance, Washington, DC
10. Smith N.L., Savage P.J., Heckbert S.R., et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus. The Cardiovascular Health Study. J Am Geriatr Soc 50 (2002) 416-423
11. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 Suppl 1 (2005) S4-S79
12. American Geriatrics Society. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51 Suppl 1 (2003) S265-S280
13. American Medical Directors Association. Managing Diabetes in the Long-Term Care Setting. Clinical Practice Guideline (2002), American Medical Directors Association, Columbia, MD
14. Zarowitz B.J., Stefanacci R., Hollenack K.O., and Shea T. The application of evidence-based principles of care in older persons (Issue 1). Osteoporosis. J Am Med Dir Assoc 7 (2006) 102-108
15. Davis S., and Alonso M.D. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 18 (2004) 60-68
16. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 332 (1998) 837-853
17. Anonymous. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 276 (1996) 1409-1415
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
19. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
20. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 345 (2001) 870-878
21. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
22. National Heart, Lung and Blood Institute, National Institute of Health, and US Department of Health and Human Services. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) (2005). http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm August 2004. Available at: www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm. Accessed July 17
23. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Multicenter randomised placebo-controlled trial. Lancet 364 (2004) 685-696
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised, placebo-controlled trial. Lancet 360 9326 (2002) 7-22
25. Grundy S.M., Cleeman J.I., Merz N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
26. Ramlo-Halsted B.A., and Edelman S.V. The natural history of type 2 diabetes. Practical points to consider in developing prevention and treatment strategies. Clinical Diabetes 18 (2000) 80-85
27. Kirplchnikov D., McFarlane S.I., and Sowers J.R. Metformin. An update. Ann Intern Med 137 (2002) 25-33
28. DeFronzo R. Pharmacologic therapy for Type 2 diabetes. Ann Intern Med 17 (1999) 281-303
29. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
30. Hay L.C., Wilmshurst E.G., and Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus. The results of continuous glucose monitoring. Diabetes Technol Therap 5 (2003) 19-26
31. Hollander P.A., Levy P., Fineman M.S., et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. A 1-year randomized, controlled trial. Diabetes Care 26 (2003) 784-790
32. Whitehouse F., Kruger D.R., Fineman M., et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25 (2002) 724-730
33. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
34. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
35. Carroll M.F., Gutierrez A., Castro M., Tsewang D., and Schade D.S. Targeting postprandial hyperglycemia. A comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 5248-5254
36. Del Prato S., Heine R.J., Keilson L., Guitard C., Shen S.G., and Emmons R.P. Treatment of patients over 64 years of age with type 2 diabetes. Experience from nateglinide pooled database retrospective analysis. Diabetes Care 26 (2003) 2075-2080
37. Yki-Jarvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
38. Riddle M., Rosenstock J., and Gerich J. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086